| Stereotactic Body Radiotherapy for Prostate Cancer (NCT01352598) | Mercy Research | 2011-06-01 |
| Hypofractionated Stereotactic Body Radiation Therapy as a Boost to the Prostate (NCT01508390) | Boston Medical Center | 2011-06-01 |
| Study of Lanreotide in Non Metastatic Castration-resistant Prostate Cancer Patients (NCT01313273) | Ipsen | 2011-06-01 |
| Metformin With Standard Taxotere and Prednisone in the Treatment of Castration Resistant Prostate Cancer (NCT01478308) | New Mexico Cancer Research Alliance | 2011-06-01 |
| A Study of Prostate and pelvIs Versus prOsTate Alone Treatment for Locally Advanced Prostate Cancer (NCT01685190) | Institute of Cancer Research, United Kingdom | 2011-06-01 |
| Clinical Validity and Utility of Genomic-targeted Chemoprevention of PCa: Aim 4a (NCT02381015) | Endeavor Health | 2011-06-01 |
| Ultrasound Imaging in Finding Prostate Cancer in Patients Undergoing Surgery (NCT02024178) | NYU Langone Health | 2011-06-01 |
| Ph Ib/IIa Study of Cabazitaxel Plus Bavituximab in Castration-resistant Prostate Cancer (NCT01335204) | Medical University of South Carolina | 2011-06-01 |
| Prostate Cancer Imaging With Radioactive Tracer and Ultrasound Detector Compared to MRI and ProstaScint (NCT01394042) | Radiological Associates of Sacramento Medical Group Inc. | 2011-06-01 |
| Phase II PAP Plus GM-CSF Versus GM-CSF Alone for Non-metastatic Prostate Cancer (NCT01341652) | University of Wisconsin, Madison | 2011-05-23 |
| A Study to Test if Enzalutamide is Effective and Safe in Prostate Cancer Patients Who Have Never Had Hormone Therapy (NCT01302041) | Astellas Pharma Inc | 2011-05-06 |
| Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer (NCT01308567) | Sanofi | 2011-05-05 |
| IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen (NCT01314118) | Janssen Biotech, Inc. | 2011-05-04 |
| Early Rehabilitation of Cancer Patients (NCT01588262) | Haukeland University Hospital | 2011-05-01 |
| Assessing the Potential for Reduced Toxicity Using Focal Brachytherapy in Early Stage, Low Volume Prostate Cancer (NCT01354951) | Memorial Sloan Kettering Cancer Center | 2011-05-01 |
| Prostate Cancer Survivors Moving Toward Exercise (PROMOTE) Trial (NCT01410656) | University of Alberta | 2011-05-01 |
| A Comparison of Totally Intravenous and Inhalation Anesthesia for Intraocular Pressure During Robot-Assisted Laparoscopic Radical Prostatectomy (NCT01744262) | Yonsei University | 2011-05-01 |
| Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies. (NCT01353625) | Celgene | 2011-04-25 |
| Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer (NCT01308580) | Sanofi | 2011-04-01 |
| PSA Levels and Biopsy Samples After Implant Radiation and Hormone Therapy in Patients With Stage I or Stage II Prostate Cancer (NCT00898326) | Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan | 2011-04-01 |
| PET Imaging Characteristics of C11-Acetate in Patients With Recurrent Prostate Carcinoma (NCT01304485) | Phoenix Molecular Imaging | 2011-04-01 |
| Castration Compared to Castration Plus Metformin as First Line Treatment for Patients With Advanced Prostate Cancer (NCT01620593) | The University of Texas Health Science Center at San Antonio | 2011-04-01 |
| Initiation of Androgen Deprivation Therapy for Prostate Cancer Using Degarelix Followed by Leuprolide (NCT01344564) | Urology of Virginia | 2011-04-01 |
| DAPROCA Pelvic Lymph Node Irradiation to Prostate for High Risk Prostate Cancer: Phase I/II Study (NCT01417676) | University of Aarhus | 2011-04-01 |
| MRI in Diagnosing Prostate Cancer (NCT01292291) | University College London Hospitals | 2011-04-01 |
| A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck (NCT01059643) | Eli Lilly and Company | 2011-04-01 |
| Trial of Hypofractionated IMRT Boost Versus Conventional IMRT Boost for Localized High Risk Prostate Cancer (NCT04239599) | Sunnybrook Health Sciences Centre | 2011-03-31 |
| Maximal Androgen Depletion Followed by Randomization of Maximal Androgen Ablation With Molecular Targeted Therapies (NCT01254864) | M.D. Anderson Cancer Center | 2011-03-16 |
| A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer (NCT01234311) | Active Biotech AB | 2011-03-01 |
| Telephone Counseling-Mailed Materials Versus Internet Interventions in Overweight Cancer Survivors (NCT01311856) | M.D. Anderson Cancer Center | 2011-03-01 |
| Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer (NCT01317641) | Orion Corporation, Orion Pharma | 2011-03-01 |
| 3D Recording of a Trans-rectal Prostate Biopsy (NCT01314456) | HaEmek Medical Center, Israel | 2011-03-01 |
| A Study of the Safety and Pharmacokinetics of Escalating Doses of DSTP3086S in Patients With Metastatic Castration-Resistant Prostate Cancer (NCT01283373) | Genentech, Inc. | 2011-03-01 |
| Comparative Effectiveness Analysis of Surgery and Radiation (CEASAR) for Localized Prostate Cancer (NCT01326286) | Vanderbilt University | 2011-03-01 |
| Carboplatin and Paclitaxel in Patients With Metastatic, Castrate-Resistant Prostate Cancer (NCT01558492) | Weill Medical College of Cornell University | 2011-03-01 |
| A Pilot Study of 123I-MIP-1072 SPECT/CT Imaging With Optional Compact Gamma Camera Probe Imaging in Men With Prostate Cancer Undergoing Prostatectomy (NCT01279785) | Molecular Insight Pharmaceuticals, Inc. | 2011-03-01 |
| BOTOX in Men With Prostate Cancer With Lower Urinary Tract Symptoms(LUTS)/Benign Prostatic Hyperplasia (BPH) (NCT01520441) | The University of Texas Health Science Center, Houston | 2011-03-01 |
| T-cell-immunity During Standard Radiotherapy in Localised Prostate Cancer (NCT01376674) | University Hospital Tuebingen | 2011-03-01 |
| Hormone Sensitive Prostate Cancer Patients Switched to Degarelix Therapy After Failing on GnRH Agonists (NCT01366053) | CMX Research | 2011-03-01 |
| Medico-economic Evaluation of IMRT by Hi Art, RapidArc, VMAT Therapy in Prostate, Cervix and Anal Canal Cancers (NCT01325961) | Institut Cancerologie de l'Ouest | 2011-03-01 |
| Radiosensitizing and Radioprotectve Effects of Curcumin in Prostate Cancer (NCT01917890) | Shahid Beheshti University of Medical Sciences | 2011-03-01 |
| Docetaxel + Prednisone With or Without Radiation for Castrate Resistant Prostate Cancer (NCT01087580) | Northwestern University | 2011-03-01 |
| Characterizing Fatigue Experienced by Cancer Patients Receiving Primary Treatment and Cancer Survivors (NCT01231932) | National Institute of Nursing Research (NINR) | 2011-02-04 |
| Efficacy and Safety Study of TOOKAD® Soluble for Localised Prostate Cancer Compared to Active Surveillance. (NCT01310894) | Steba Biotech S.A. | 2011-02-01 |
| Effectiveness of Electronic Health Record-Based Interventions for Improving Follow-Up in Primary Care (NCT01346839) | Baylor College of Medicine | 2011-02-01 |
| 3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer (NCT01296672) | The University of Texas Health Science Center at San Antonio | 2011-02-01 |
| Tesetaxel in Chemotherapy-naive Patients With Progressive, Castration-resistant Prostate Cancer (NCT01296243) | Genta Incorporated | 2011-02-01 |
| Feasibility Study on a Nordic Lifestyle Intervention Trial Among Men With Prostate Cancer (NCT01300104) | Danish Cancer Society | 2011-02-01 |
| Observational Program to Assess Use of Intermittent Adjuvant Deprivation Therapy With Leuprorelin (Lucrin Depot) in Patients With Advanced Prostate Cancer (PCa) in Russia (NCT01320735) | AbbVie (prior sponsor, Abbott) | 2011-02-01 |
| Ferumoxytol Enhanced MRI for the Detection of Lymph Node Involvement in Prostate Cancer (NCT01296139) | National Cancer Institute (NCI) | 2011-01-26 |
| Radiation Therapy in Treating Patients With Relapsed Prostate Cancer After Surgery (NCT01272050) | Swiss Cancer Institute | 2011-01-06 |
| Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors (NCT01286987) | Pfizer | 2011-01-03 |
| Does Protein Restriction Inhibit Prostrate Cancer Growth (NCT01692587) | Washington University School of Medicine | 2011-01-01 |
| Hypofractionated Stereotactic Body Radiation Therapy (SBRT) (NCT01288534) | University of Michigan Rogel Cancer Center | 2011-01-01 |
| Prevention of Micro-architectural Bone Decay in Males With Non-metastatic Prostate Cancer Receiving Androgen Deprivation Therapy (ADT) (NCT01006395) | Austin Health | 2011-01-01 |
| Dose Escalation Study With Cabazitaxel in Combination With Daily Prednisolone in Patients With Hormone Refractory Prostate Cancer (NCT01324583) | Sanofi | 2011-01-01 |
| A Safety Study in Patients With Advanced Prostate Cancer Treated With FIRMAGON (NCT01234350) | Ferring Pharmaceuticals | 2011-01-01 |
| Blood for Immune Response to Provenge® in HRPC (NCT01274572) | Mary Crowley Medical Research Center | 2011-01-01 |
| Does End-fire Technique Increase Detection Rate of Prostate Cancer at First Re-biopsy Compared to Side-fire Technique? (NCT02761135) | Kronoberg County Council | 2011-01-01 |
| Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer (NCT01511874) | HanAll BioPharma Co., Ltd. | 2011-01-01 |
| North Carolina Prostate Cancer Comparative Effectiveness & Survivorship Study (NC ProCESS) (NCT02564120) | UNC Lineberger Comprehensive Cancer Center | 2011-01-01 |
| Prospective Multicentre Non-interventional Study of VANTAS® for the Treatment of Patients With Advanced Prostate Cancer (NCT01574846) | Orion Corporation, Orion Pharma | 2011-01-01 |
| MR-guided Focused Ultrasound Treatment of Prostate Cancer: Focal Therapy for Locally Non-Advanced Disease (NCT01522118) | University of Roma La Sapienza | 2011-01-01 |
| Diet in Altering Disease Progression in Patients With Prostate Cancer on Active Surveillance (NCT01238172) | Alliance for Clinical Trials in Oncology | 2011-01-01 |
| Therapy for Erectile Dysfunction Adaptation of ACT for Compliance With an Erectile Rehabilitation Program (NCT01275404) | Memorial Sloan Kettering Cancer Center | 2010-12-28 |
| Metformin Hydrochloride as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Prostate Cancer (NCT01243385) | Swiss Cancer Institute | 2010-12-23 |
| Feasibility of Hormones and Radiation for Intermediate or High Risk Prostate Cancer (NCT01342367) | University of Chicago | 2010-12-17 |
| Feasibility of a Chemotherapy With Docetaxel-Prednisone for Castration-resistant Metastatic Prostate Cancer Elderly Patients (NCT01254513) | UNICANCER | 2010-12-09 |
| Experimental Therapeutic Cancer Vaccine Created In-situ in Patients With Stage II-Stage IV Cancer (NCT01065441) | Michael Har-Noy | 2010-12-01 |
| CT-validation of Ultrasound Based Planning for High Dose Rate (HDR) Prostate Brachytherapy Using Vitesse (NCT01248741) | British Columbia Cancer Agency | 2010-12-01 |
| Biomarkers in Bone Marrow and Blood Samples From Patients With Prostate Cancer Treated With Ketoconazole (NCT01275651) | Alliance for Clinical Trials in Oncology | 2010-12-01 |
| Equivalence of Intramuscular (IM) Versus Subcutaneous (SC) Applications of Long Acting Pamorelin 11.25 mg (NCT01257425) | Ipsen | 2010-12-01 |
| Decision Support Interventions (DESI) for Prostate Cancer Screening and Treatment - Study 2 (NCT01244568) | University of North Carolina, Chapel Hill | 2010-12-01 |
| A Study of 99mTc-MIP-1404 and 99mTc-MIP-1405 in Patients With Metastatic Prostate Adenocarcinoma and Healthy Volunteers (NCT01261754) | Molecular Insight Pharmaceuticals, Inc. | 2010-12-01 |
| A Study of Degarelix in Taiwanese Patients With Prostate Cancer (NCT01220869) | Ferring Pharmaceuticals | 2010-12-01 |
| Utilizing A Genomic Sig for "BRCAness" to Eval the Efficacy of Satraplatin in Men With Met. Castration Resistant Prostate Ca (NCT01289067) | William K. Oh | 2010-12-01 |
| Configuration of a New Prostate Disease Nomogram Predicting Prostate Biopsy Outcome (NCT01826617) | St. Luke's Medical Center, Philippines | 2010-12-01 |
| Study Comparing Orteronel Plus Prednisone in Participants With Metastatic Castration-Resistant Prostate Cancer. (NCT01193257) | Millennium Pharmaceuticals, Inc. | 2010-11-15 |
| A Study of MDV3100 to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of in Prostate Cancer Patients (NCT01284920) | Astellas Pharma Inc | 2010-11-02 |
| Doxorubicin-GnRH Agonist Conjugate AEZS-108 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer (NCT01240629) | University of Southern California | 2010-11-02 |
| The Effects of Epidural Anesthesia on the Bioavailability of Nitric Oxide and Renal Function in Patients Undergoing Laparoscopic Surgery (NCT01325844) | Yonsei University | 2010-11-01 |
| Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer (NCT01188187) | Achieve Life Sciences | 2010-11-01 |
| Study in Men With Prostate Cancer to Assess the Safety, Pharmacokinetics and Testosterone-Lowering Efficacy of TAK-448 (NCT01132404) | Millennium Pharmaceuticals, Inc. | 2010-11-01 |
| Redes III Patient Navigator Qol Study (NCT02275754) | The University of Texas Health Science Center at San Antonio | 2010-11-01 |
| Hyaluronic Acid for Hypofractionated Prostate Radiotherapy (NCT02165020) | Hospices Civils de Lyon | 2010-11-01 |
| Magnetic Resonance Imaging-Transrectal Ultrasound Fusion Image-Guided Prostate Biopsy Following Radical Prostatectomy in Patients With Prostate Cancer (NCT01764347) | University of Southern California | 2010-11-01 |
| Study of Hypo-fractionated Proton Radiation for Low Risk Prostate Cancer (NCT01230866) | Proton Collaborative Group | 2010-11-01 |
| Pilot Study of Secondary Causes of Osteopenia/Osteoporosis in Adults With Breast and Prostate Cancer (NCT01277562) | City of Hope Medical Center | 2010-11-01 |
| International,Multi-Center,Open Label,Randomized Study Assessing the Safety and Efficacy of a Monthly Dosing Regimen of Ozarelix Versus Goserelin Depot in Men With Prostate Cancer (NCT01252693) | Spectrum Pharmaceuticals, Inc | 2010-11-01 |
| Anti-OX40, Cyclophosphamide (CTX) and Radiation in Patients With Progressive Metastatic Prostate Cancer (NCT01303705) | Providence Health & Services | 2010-10-14 |
| Hypofractionated SBRT For Prostate Cancer (NCT00977860) | Adam Olson | 2010-10-07 |
| A Degarelix Trial in Patients With Prostate Cancer (NCT01242748) | Ferring Pharmaceuticals | 2010-10-01 |
| Study Comparing Orteronel Plus Prednisone in Participants With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer (NCT01193244) | Millennium Pharmaceuticals, Inc. | 2010-10-01 |
| A Study Into the Effectivity and Safety of Firmagon, Prescribed for Treatment of Patients With Advanced Prostate Cancer (NCT01215526) | Ferring Pharmaceuticals | 2010-10-01 |
| Hyperpolarized Pyruvate Injection in Subjects With Prostate Cancer (NCT01229618) | University of California, San Francisco | 2010-10-01 |
| L-Arginine Supplementation With or Without Enzyme Inhibitors Treating Erectile Function of Prostate Cancer Survivors (NCT01105130) | Wake Forest University Health Sciences | 2010-10-01 |
| A Study of Olaratumab (IMC-3G3) in Prostate Cancer (NCT01204710) | Eli Lilly and Company | 2010-10-01 |
| A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer (NCT01212991) | Pfizer | 2010-09-16 |
| Abiraterone Post Ketoconazole for Prostate Cancer (NCT01199146) | University of California, San Francisco | 2010-09-10 |
| Changes in Brown Adipose Tissue Activity In Men Receiving Androgen Deprivation Therapy for Prostate Cancer (NCT01226888) | Massachusetts General Hospital | 2010-09-01 |